Search research articles
Contact Us
Filters
Showing results (121-130 of 159) with videos related to
Page
of 16
Sort By:
Journal of Medicinal Chemistry
|
June 19, 2013
Targeting gain of function and resistance mutations in Abl and KIT by hybrid compound design
André Richters, Julia Ketzer, Matthäus Getlik, et al.
Chemmedchem
|
February 16, 2022
Covalent Allosteric Inhibitors of Akt Generated Using a Click Fragment Approach
Leandi van der Westhuizen, Jörn Weisner, Abu Taher, et al.
Angewandte Chemie (International Ed. in English)
|
May 26, 2017
Phenotypic Identification of a Novel Autophagy Inhibitor Chemotype Targeting Lipid Kinase VPS34
Lucas Robke, Luca Laraia, Marjorie A Carnero Corrales, et al.
Journal of Medicinal Chemistry
|
August 24, 2017
Design, Synthesis, and Biological Evaluation of Novel Type I<sup>1</sup>/<sub>2</sub> p38α MAP Kinase Inhibitors with Excellent Selectivity, High Potency, and Prolonged Target Residence Time by Interfering with the R-Spine
Niklas M Walter, Heike K Wentsch, Mike Bührmann, et al.
Journal of Medicinal Chemistry
|
August 31, 2017
Structure-Guided Development of Covalent and Mutant-Selective Pyrazolopyrimidines to Target T790M Drug Resistance in Epidermal Growth Factor Receptor
Julian Engel, Steven Smith, Jonas Lategahn, et al.
Chemical Science
|
April 19, 2019
Structural and chemical insights into the covalent-allosteric inhibition of the protein kinase Akt
Niklas Uhlenbrock, Steven Smith, Jörn Weisner, et al.
Angewandte Chemie (International Ed. in English)
|
June 26, 2015
Covalent-Allosteric Kinase Inhibitors
Jörn Weisner, Rajesh Gontla, Leandi van der Westhuizen, et al.
Nature Communications
|
September 7, 2021
Cellular model system to dissect the isoform-selectivity of Akt inhibitors
Lena Quambusch, Laura Depta, Ina Landel, et al.
Journal of Medicinal Chemistry
|
December 4, 2014
Combining X-ray crystallography and molecular modeling toward the optimization of pyrazolo[3,4-d]pyrimidines as potent c-Src inhibitors active in vivo against neuroblastoma
Cristina Tintori, Anna Lucia Fallacara, Marco Radi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 29, 2025
Phase 2 trial of ponatinib in patients with metastatic gastrointestinal stromal tumor following failure or intolerance of prior therapy with imatinib (POETIG trial)
Johanna Falkenhorst, Phillipp Ivanyi, Tom Schulz, et al.
Page
of 16
Search research articles
Search
Showing results (121-130 of 159) with videos related to
Sort By:
Page
of 16
Journal of Medicinal Chemistry
|
June 19, 2013
Targeting gain of function and resistance mutations in Abl and KIT by hybrid compound design
André Richters, Julia Ketzer, Matthäus Getlik, et al.
Chemmedchem
|
February 16, 2022
Covalent Allosteric Inhibitors of Akt Generated Using a Click Fragment Approach
Leandi van der Westhuizen, Jörn Weisner, Abu Taher, et al.
Angewandte Chemie (International Ed. in English)
|
May 26, 2017
Phenotypic Identification of a Novel Autophagy Inhibitor Chemotype Targeting Lipid Kinase VPS34
Lucas Robke, Luca Laraia, Marjorie A Carnero Corrales, et al.
Journal of Medicinal Chemistry
|
August 24, 2017
Design, Synthesis, and Biological Evaluation of Novel Type I<sup>1</sup>/<sub>2</sub> p38α MAP Kinase Inhibitors with Excellent Selectivity, High Potency, and Prolonged Target Residence Time by Interfering with the R-Spine
Niklas M Walter, Heike K Wentsch, Mike Bührmann, et al.
Journal of Medicinal Chemistry
|
August 31, 2017
Structure-Guided Development of Covalent and Mutant-Selective Pyrazolopyrimidines to Target T790M Drug Resistance in Epidermal Growth Factor Receptor
Julian Engel, Steven Smith, Jonas Lategahn, et al.
Chemical Science
|
April 19, 2019
Structural and chemical insights into the covalent-allosteric inhibition of the protein kinase Akt
Niklas Uhlenbrock, Steven Smith, Jörn Weisner, et al.
Angewandte Chemie (International Ed. in English)
|
June 26, 2015
Covalent-Allosteric Kinase Inhibitors
Jörn Weisner, Rajesh Gontla, Leandi van der Westhuizen, et al.
Nature Communications
|
September 7, 2021
Cellular model system to dissect the isoform-selectivity of Akt inhibitors
Lena Quambusch, Laura Depta, Ina Landel, et al.
Journal of Medicinal Chemistry
|
December 4, 2014
Combining X-ray crystallography and molecular modeling toward the optimization of pyrazolo[3,4-d]pyrimidines as potent c-Src inhibitors active in vivo against neuroblastoma
Cristina Tintori, Anna Lucia Fallacara, Marco Radi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 29, 2025
Phase 2 trial of ponatinib in patients with metastatic gastrointestinal stromal tumor following failure or intolerance of prior therapy with imatinib (POETIG trial)
Johanna Falkenhorst, Phillipp Ivanyi, Tom Schulz, et al.
Page
of 16